Biomedical subjects

A Cristina Rossi

Publications and source records attributed to A Cristina Rossi.

3 recordsLinked to original sources

PubMed2006

A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis.

OBJECTIVE: To investigate the role of adjuvant treatment with gonadotropin-releasing-hormone agonist (GnRHa) following conservative surgical treatment of endometriosis. STUDY DESIGN: Sixty patients in the reproductive age (mean age 28.6 years), with symptomatic stages III and IV endometriosis following laparoscopic surgery and without previous hormonal treatment were enrolled in a prospective, randomized, controlled trial to compare the effects of 3-month treatment with triptorelin depot-3.75 i.m. (30 patients) versus expectant management using placebo injection (30 patients). RESULTS: Six patients (one in triptorelin group and five in placebo group) were lost at follow-up, the remaining 54 were suitable for analysis. Pelvic pain persistence or recurrence, endometrioma relapses and pregnancy rate were evaluated during a 5-year follow-up. The results of 29 cases treated with triptorelin and 25 that received placebo did not show significant differences in pain recurrence (P=1, RR=0.94, 95% CI=0.57-1.55), endometrioma relapse (P=0.67, RR=1.29, 95% CI=0.66-2.50), and pregnancy rate in infertile women (P=0.80, RR=0.81, 95% CI=0.37-1.80). Curves of time of pain recurrence and pregnancy during 5-year follow-up did not show significant differences between the two groups (P=0.79 and P=0.51, respectively, using Mantel-Haenzsel logrank test). CONCLUSION: Triptorelin treatment after operative laparoscopy for stage III/IV endometriosis does not appear to be superior to expectant management in terms of prevention of symptoms recurrence and endometrioma relapse, and has no influence on pregnancy rate in endometriosis-associated infertility.

Adult↗

PubMed2006

Prognosis of very large first-trimester hematomas.

OBJECTIVE: The aim of this study was to evaluate the outcome of pregnancies complicated by very large hematomas in the first trimester. METHODS: Between January 2001 and January 2006, 8085 patients between 5 and 14 weeks' gestation underwent routine first-trimester ultrasonographic examinations at our practice. Of these, 30 patients had a "very large" (> 50% of the gestational sac) intrauterine hematoma. These 30 patients were further classified according to pregnancy outcome (normal or adverse), maternal age, vaginal bleeding, crown-rump length, gestational age at diagnosis of the hematoma, and position and location of the hematoma. P < .05 was considered statistically significant. RESULTS: Six patients were excluded (4 were still pregnant, and 2 were lost to follow-up), leaving 24 patients eligible for analysis, of which 11 (46%) had adverse outcomes and 13 (54%) had normal outcomes. The group with adverse outcomes had a significantly lower gestational age at diagnosis than the second group (7 weeks [range, 5.7-8.4 weeks] versus 8.4 weeks [range, 6.2-14 weeks]; P = .0227), but crown-rump length, vaginal bleeding, and position and location of the hematoma were similar. CONCLUSIONS: Very large hematomas were associated with adverse outcome in 46% of the pregnancies. Vaginal bleeding was not associated with a poor prognosis. Neither position nor location of the placental hematoma was related to the outcome; however, when the hematoma was diagnosed at an early gestational age, the outcomes were worse.

Adult↗

PubMedDate not supplied

Timing of fetal growth acceleration in women with insulin-dependent diabetes.

OBJECTIVE: To detect differences in growth profiles of fetuses of type 1 diabetic mothers, aiming at finding when growth acceleration happens in large-for-gestational-age (LGA) fetuses at birth as compared with appropriate-for-gestational-age (AGA) fetuses and the relationship between growth profile and diabetic control throughout pregnancy. METHODS: Ninety-eight mother-infant pairs with well-controlled insulin-dependent diabetes were included. The fetal abdominal circumference was measured every 3 weeks by ultrasound between 20 and 36 weeks' gestation. Metabolic control was evaluated by monthly measurement of glycated haemoglobin concentration and weekly measurement of the capillary blood glucose levels. RESULTS: A significant difference in fetal abdominal circumference was detected at 24 weeks. The fetuses in both the LGA and the AGA groups were able to maintain their growth profile (i.e., accelerated or normal growth) throughout pregnancy. The parameters of glucose control were similar for both groups at any gestational age. CONCLUSIONS: Fetal growth acceleration is identifiable by ultrasound at about 24 weeks. 'Normal' parameters of glucose control during the 1st trimester and throughout pregnancy do not seem to be related to the growth potential of the LGA fetus of a diabetic mother. Fluctuations in glucose levels rather than basal levels are probably more determinant in fetal growth acceleration.

Adult↗